PLA in Tissue Engineering: Scaffolds for Regenerative Medicine

August 2, 2026

You are evaluating scaffold materials for a regenerative medicine program, and the questions come quickly. Will the polymer support cell attachment? Will it degrade on the right timeline? Can it be processed into a porous, load-bearing structure at production scale? For many buyers and researchers, the answer is polylactic acid (PLA). This guide explains why PLA is a reliable scaffold material, how it is fabricated, where it performs in bone, cartilage, skin, and vascular repair, and what to verify before you commit to a supplier.

Clean patient care products in a healthcare setting

What Tissue Engineering Needs from a Scaffold

A scaffold is a temporary substitute for the extracellular matrix (ECM). It must be biocompatible, provoking no chronic immune response. It must be biodegradable, resorbing at a rate matched to new tissue formation. It must be porous, with interconnected pores — commonly 100–300 µm for bone — that allow cell infiltration, nutrient transport, and vascular ingrowth. It must provide mechanical support while new matrix matures, and its surface must favor protein adsorption and cell attachment. Miss any of these, and outcomes suffer regardless of cell quality. As Santoro and colleagues summarize in Advanced Drug Delivery Reviews, scaffold chemistry and architecture are designed to be recognized and remodeled by cells (PubMed).

Why PLA Is Widely Used for Scaffolds

PLA is a biodegradable aliphatic polyester made from renewable lactic acid. Four practical properties explain its popularity. Regulatory track record: PLA has decades of use in cleared absorbable and implantable devices, which simplifies qualification. Processability: PLA melts, dissolves, and spins readily, so it forms fibers, foams, films, and 3D-printed constructs. Tunable degradation: the hydrolysis rate is adjusted through molecular weight, crystallinity, stereochemistry (PLLA versus PDLLA), and copolymerization with glycolic acid. Safety data: a long clinical history gives buyers a documented baseline for risk assessment.

Fabrication Methods for PLA Scaffolds

Fabrication method controls pore architecture, mechanical behavior, and cell response. Four approaches dominate practice.

Fabrication method	Key advantage	Typical application
Electrospinning	Nanofiber meshes that mimic ECM fibrils; high surface area	Skin and vascular grafts
Solvent casting with particulate leaching	Controllable porosity and pore size	Bone void fillers
3D printing (FDM)	Patient-specific geometry; reproducible pore networks	Bone and cartilage constructs
Freeze drying	Highly porous, soft sponges	Soft tissue scaffolds

Electrospun PLA nanofibers are among the most studied scaffold formats, with fiber diameter and alignment tuned for contact guidance. For bone, 3D printing with PLA and bioceramic composites produces reproducible macro- and microporosity in preclinical models (Acta Biomaterialia, 2023).

PLA Scaffolds in Bone, Cartilage, Skin, and Vascular Repair

Bone. 3D-printed PLA–hydroxyapatite (HA) scaffolds pair printability with osteoconductive calcium phosphate; a 2023 Polymers study characterized how HA content changes the physicochemical properties of printed constructs (MDPI). Cartilage and connective tissue. Electrospun PLA–polycaprolactone (PCL) nanofiber scaffolds have been evaluated for anterior cruciate ligament injury, where blended fibers balance stiffness and elasticity (MDPI). Skin. Electrospun PLA mats support fibroblast adhesion and wound coverage in experimental models. Vascular. Tubular PLA and PLA-blend grafts maintain patency while degrading, a direction reviewed in Advanced Drug Delivery Reviews (2016).

Sterile disposable medical products

Blends and Composites Extend PLA's Range

Neat PLA is stiff and hydrophobic, so most clinically oriented work uses blends. PLA–HA adds bioactivity and local pH buffering for bone applications. PLA–PCL adds toughness and slows degradation for flexible tissues. PLA–gelatin or PLA–chitosan improves hydrophilicity and initial cell attachment. Blending also tunes mechanics: the PLA–PCL ligament scaffold work shows how fiber composition adjusts tensile behavior for load-bearing connective tissue.

Limitations and How Research Addresses Them

PLA has documented limitations. Hydrophobicity reduces initial cell adhesion; plasma treatment, surface coatings, and hydrophilic blends address it. Degradation releases lactic acid, which can lower local pH; HA-containing composites buffer the microenvironment. Mechanical strength declines as hydrolysis progresses, which matters in load-bearing sites; annealing, copolymerization, and composite reinforcement slow the loss. None is disqualifying — each simply informs scaffold selection.

Regulatory and Buying Considerations

For clinical translation, scaffolds should meet ISO 10993 biocompatibility requirements, covering cytotoxicity, sensitization, irritation, and systemic toxicity. Buyers should request certificates of analysis, medical-grade documentation, molecular weight and residual monomer data, and sterilization compatibility (ethylene oxide, gamma, or e-beam). Confirm lot-to-lot consistency and match grade to intended use — industrial PLA is not equivalent to implant-grade material. Our guide on PLA in medical devices covers the wider device landscape, and our comparison of PHA scaffolds in bone, skin, and cartilage repair helps when benchmarking alternative polyesters.

PLA remains one of the most practical starting points in absorbable scaffold design: processable, tunable, and supported by a deep literature. Pairing it with ceramics, flexible polyesters, or hydrophilic polymers addresses its limits without surrendering its strengths. When you evaluate suppliers, weigh documented performance data, material traceability, and regulatory files as heavily as price — the scaffold you select today shapes the results you report tomorrow.

Facilities shifting toward greener purchasing often start with high-volume disposables. CliniEco offers PLA biodegradable underpads and PLA bed sheets as a practical, certified starting point for Canadian clinics and long-term care homes.